Colorectal and pancreatic cancer biomarker study

Prodrome Sciences Inc.; Chiba University Hospital, Division of Clinical Mass Spectrometry; Chiba Cancer Center; and Chiba Foundation for Health Promotion & Disease Prevention are analyzing over 3,000 samples of Japanese persons with confirmed diagnoses of colorectal or pancreatic cancer and persons of average risk.

The goal of the research collaboration is to determine if Prodrome Sciences’ new ProdromeScan technology can improve the accuracy of Prodrome Sciences’ current Prodrome-CRC blood test for colorectal cancer and Prodrome-PAC blood test for pancreatic cancer, which simultaneously measure 20 different GTA (gastrointestinal tract acid) species. Prodrome Sciences’ new ProdromeScan technology simultaneously measures not only GTAs, but also other serum metabolites known to be associated with colorectal cancer and pancreatic cancer, such as plasmalogens, phosphatidylethanolamines, and phosphatidylcholines.

Prodrome Sciences has made significant operational and technological improvements to Dr. Goodenowe’s original non-targeted metabolomics technology. The new ProdromeScan technology measures thousands of serum metabolites in a single drop of blood. Unlike Dr. Goodenowe’s original technology, which was designed for biomarker discovery research, ProdromeScan is designed for use in routine, high-volume, clinical laboratories.